Correction to: Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma

Ann Hematol. 2018 Dec;97(12):2529-2530. doi: 10.1007/s00277-018-3455-x.

¹ Department of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. dmaruyam@ncc.go.jp.
² Department of Hematology, National Cancer Center Hospital East, Kashiwa, Japan.
³ Department of Hematology and Oncology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan.
⁴ Okayama University Hospital, Okayama, Japan.
⁵ Osaka University Hospital, Osaka, Japan.
⁶ Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
⁷ Hokkaido Cancer Center, Sapporo, Japan.
⁸ Kyushu Cancer Center, Fukuoka, Japan.
⁹ The Cancer Institute Hospital, Tokyo, Japan.
¹⁰ Tokai University Hospital, Isehara, Japan.
¹¹ Shikoku Cancer Center, Matsuyama, Japan.
¹² Kumamoto Medical Center, Kumamoto, Japan.
¹³ Hyogo Cancer Center, Akashi, Japan.
¹⁴ Tohoku University Hospital, Sendai, Japan.
¹⁵ Gunma University Hospital, Maebashi, Japan.
¹⁶ University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan.
¹⁷ Shimane University Hospital, Izumo, Japan.
¹⁸ Fukuoka University Hospital, Fukuoka, Japan.
¹⁹ Fukui University Hospital, Fukui, Japan.
²⁰ Aichi Medical University, Nagakute, Japan.
²¹ Department of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

Abstract

The original version of this article contained a mistake in Fig. 4. The horizontal axis should be 36 instead of 60.